Table 1 Clinicopathological characteristics of advanced ESCC patients treated with ICI + CT
Characteristics | Total | Non-Responders | Responders | P |
|---|---|---|---|---|
(n = 64) | (n = 32) | (n = 32) | ||
Age, year | 0.206 † | |||
<60 | 37 (57.8%) | 16 (50%) | 21 (65.6%) | |
≥ 60 | 27 (42.2%) | 16 (50%) | 11 (34.4%) | |
Gender, n (%) | 1.000 † | |||
Female | 10 (15.6%) | 5 (15.6%) | 5 (15.6%) | |
Male | 54 (84.4%) | 27 (84.4%) | 27 (84.4%) | |
BMI, n (%) | 1.000 † | |||
<18.5 | 4 (6.3%) | 2 (6.3%) | 2 (6.3%) | |
≥ 18.5 and <24 | 46 (71.9%) | 23 (71.9%) | 23 (71.9%) | |
≥ 24 | 14 (21.9%) | 7 (21.9%) | 7 (21.9%) | |
T stage, n (%) | 0.633 § | |||
T1 | 3 (4.7%) | 1 (3.1%) | 2 (6.3%) | |
T2 | 11 (17.2%) | 5 (15.6%) | 6 (18.8%) | |
T3 | 31 (48.4%) | 18 (56.3%) | 13 (40.6%) | |
T4 | 19 (29.7%) | 8 (25%) | 11 (34.4%) | |
N stage, n (%) | 0.585 † | |||
N1 | 18 (28.1%) | 10 (31.3%) | 8 (25%) | |
N2 | 24 (37.5%) | 10 (31.3%) | 14 (43.8%) | |
N3 | 22 (34.4%) | 12 (37.5%) | 10 (31.3%) | |
Metastasis, n (%) | 19 (29.7%) | 13 (40.6%) | 6 (18.8%) | 0.055 † |
Decreased hemoglobin, n (%) | 6 (9.4%) | 4 (12.5%) | 2 (6.3%) | 0.668 § |
Normal albumin, n (%) | 64 (100%) | 32 (100%) | 32 (100%) | NA |
Increased leucocyte, n (%) | 10 (15.6%) | 5 (15.6%) | 5 (15.6%) | 1.000 † |
C-reactive protein≥10 mg/L, n (%) | 31 (48.4%) | 13 (40.6%) | 18 (56.3%) | 0.211 † |
Underlying diseases, n (%) | 21 (32.8%) | 10 (31.3%) | 11 (34.4%) | 0.790 † |